Redeye retains its Base Case despite cutting its short-term EBIT forecasts slightly. We raised our ARR, sales, and OPEX forecasts due to FX – where both the EUR and USD appreciated during Q1. Combined with a slight increase in underlying OPEX assumptions, we cut our short-term EBIT forecast somewhat while slightly increasing the long- and mid-term.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/